BeyondSpring (NASDAQ: BYSI) stock is up 230% today. Read on to find out why and where the best places are to buy it.
If you want to invest in BeyondSpring shares, or if you simply want to find out a little more about the company, this article contains the answers to your queries. Read on to find out what the company is, why it is currently surging in value, and whether or not you should buy BYSI shares right now.
Before we get into any of that, feel free to check out the section directly below. There, you can find our list of the best places to buy BeyondSpring stock in the UK and worldwide.
How & where to buy BeyondSpring stock online
To buy BYSI shares, click on one of the links below, deposit funds, and purchase the number of shares you want.
These are the best platforms to buy, sell and trade BeyondSpring stock thanks to their low fees and easy-to-use trading interfaces:
eToro is one of the world's leading multi-asset trading platforms offering some of the lowest commission and fee rates in the industry. It's social copy trading features make it a great choice for those getting started.
Financial company driven by technology and offering all-in-one self-directed investment platform that provides excellent user experience.
What is BeyondSpring?
Founded in 2010 and headquartered in New York, United States, it is a clinical stage biopharmaceutical company that is focussed on the development and commercialisation of immuno-oncology cancer therapies.
The BeyondSpring share price has surged following the news of its “positive top-line data" from a trial of Plinabulin combined with Docetaxel to treat second- and third-line non-small-cell lung cancer (EGFR wild type) compared with Docetaxel alone.
Should I buy BeyondSpring shares today?
If you think Plinabulin can achieve commercial success in the near future, and if you think the remainder of BeyondSpring’s product line-up can make waves in the medical space, buying BYSI shares now and holding them could be a great way to speculate on future growth.
Just be wary of the risks of investing, which are especially heightened when dealing with biopharmaceutical companies.
BeyondSpring price target 2021
Our BYSI price target is as follows: a 12-month high of $39, with a median of $33.50 and a low of $25.